InvestorsHub Logo
Followers 58
Posts 10130
Boards Moderated 1
Alias Born 09/21/2016

Re: XenaLives post# 450234

Wednesday, 01/31/2024 9:02:23 AM

Wednesday, January 31, 2024 9:02:23 AM

Post# of 461471
Break the bubble of serial thinking . CNS diseases present complexity which will not be solved (unless someone get very lucky) looking at one variable at a time. Huh, no WONDER it has been stuck in Amyloid spot thinking for so long.

"As a biopharmaceutical Company with a proprietary late stage pipeline for CNS indications, Anavex brings expertise in precision medicine drug development to the partnership and we are excited to collaborate with Partex and fully leverage AI to expand beyond our R&D into healthcare sales marketing to bring better treatment options to patients in a patient centric way,” said, Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.



https://www.anavex.com/post/anavex-life-sciences-and-partex-group-announce-strategic-partnership



AVXL is way out in front on many levels. Being able to mange multiple linked variables ain't easy but that is likely the ONLY way CNS diseases trials will get BIG results that can be built on. This may happen very quickly considering the number of smart people in the room and the dimensions of the vacuum that exists and MUST be filled. I hear a great big BOOOM in our collective future...

Maybe we will finally begin to see more of , "What we did not know, we did not know. " STANDBY
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News